Mar 8, 2019
Global Microbiome Therapeutics & Diagnostics Market presents Financial market forecast through 2023 with CAGR values of all market segments outlined in the objective, SWOT analysis of the global market and Geographical analysis and challenges within key topographies.

Pune, India - March 8, 2019 /MarketersMedia/ —
This report provides a comprehensive overview of the size of the microbiome therapeutic and diagnostic market, segmentation of the market (Gastrointestinal, Metabolic, Cancer, Neurological, Autoimmune, Skin), key players and the potential of therapies that are in clinical trials. Kelly Scientific analysis indicates that the global Microbiome Therapeutic and Diagnostic Market is worth $1.13 billion in 2018 and will grow at a CAGR of 19.03% over five years to $2.7 billion in 2023. The majority of the market will be dominated by microbiome based therapeutics, with an estimate of x%, compared to x% in microbiome diagnostics. This report describes the evolution of such a prospective market in eight chapters supported by over 82 tables and figures in 165 pages.
An overview of the human microbiome space that includes how the market is sub-divided into therapeutics (prebiotics, probiotics, fecal microbiota transplantation, small molecules) and diagnostics.
Global microbiome market, global breakdown, application breakdown and leading market players
Detailed account of the microbiome industry market by geography, indication and company profiles
Profiles, pipeline products, financial analysis and business strategy of the major companies in this space
Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for microbiome therapeutics and diagnostics
Insight into the challenges faced by stakeholders
Insight into the biobanking industry globally and its impact on the overall market
Description and data for the prevalence of disease types that are addressed by harnessing the human microbiota
Get Free Sample Copy of Global Microbiome Therapeutic and Diagnostic Market Research Report at https://www.reportsnreports.com/contacts/requestsample.aspx?name=1653034
The global microbiome therapeutic and diagnostic market is worth $1.13 billion in 2018 and will grow at a CAGR of 19.03% over five years to $2.7 billion in 2023. The majority of the market will be dominated by microbiome based therapeutics, with an estimate of x%, compared to x% in microbiome diagnostics. Therefore, the global microbiome therapeutics market is worth $x billion in 2018, compared to $x billion in the diagnostic space. By 2023, therapeutics will grow to $x billion, and diagnostics will grow to $x billion globally. Growth will certainly depend on a number of factors including positive results from clinical trials, continued investment and regulatory strategies.
Our analysis indicates that North America holds the lions share of the microbiome therapeutic and diagnostic market in 2018 at $x million. This compares to $x million in Europe, $x million in Asia Pacific, and $x million in the Middle East. By 2023, North America will continue to dominate the market, with a revenue of $x billion, compared to $x million in Europe, $x million in Asia Pacific, and $x million in the Middle East.
Market Applications & Therapeutic Areas
Our Analysis has identified six key therapeutic areas that the microbiome therapeutic and diagnostic market is sub-divided into, namely:
Gastrointestinal
Metabolic
Cancer
Neurological
Autoimmune
Skin Disorders
The gastrointestinal therapeutic market is the most dominant, demanding $x million in revenue in 2018, which will rise to $x million by 2023. This is mainly due to disease states such as Clostridium difficile infection, Crohn s disease, ulcerative colitis and gastroenteritis. As mentioned throughout our report, this is the key area for active clinical trials and impending drug launches. This area currently demands x% of the overall market and will tend to dominate this space for the foreseeable future. The gastrointestinal diagnostic market is currently worth $x million and is set to reach $x million by 2023.
Get Discount on this Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1653034
Competitive Landscape
The microbiome field is highly competitive, especially within the inflammatory bowel disease and Clostridium difficile infection therapeutic markets. A wide range of big pharma, biotech, early-stage companies, academic institutions, government agencies and other public and private research organizations are involved in this space. The main therapeutic competitors within the microbiome industry are as follows:
Johnson & Johnson
Novartis International
Abbvie
Takeda
Merck & Co.,
Bristol Myers Squibb
Pfizer
Seres Therapeutics
Vedanta Biosciences
Finch Therapeutics
Enterome Bioscience
Second Genome
More specifically, companies involved in C. difficile infection include Actelion Pharmaceutical, Assembly Biosciences, AzurRx, Da Volterra, Pfizer, Merck, Merus, Rebiotix, Sanofi, Seres Therapeutics, Synthetic Biologics and Summit Therapeutics. Companies within the IBS-Constipation market include Ardelyx, Allergan, Ironwood Pharmaceuticals, Synergy Pharmaceuticals, Synthetic Biologics and Takeda. Within the pertussis market GlaxoSmithKline, Mitsubishi Tanabe Pharma Corporation and Sanofi are major players. BioMarin Pharmaceutical, Synthetic Biologics, Codexis and Synlogic are involved in the PKU market. Within the diagnostic sub-market, the following are the main players:
Metabiomics - Colon Polyp and Colon Cancer Test
Origin Sciences - Colorectal Cancer (CRC) Test
Enterome/AbbVie - IBD110
Direct Purchase of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=1653034
Key Questions Answered
What are the Main Microbiome Therapeutics in the Pipeline?
What are the Main Microbiome Diagnostics in the Pipeline?
What Key Biologics are in the Pipeline?
How Many Human Therapeutic and Diagnostic Microbiome Products are in the Pipeline?
What is the Human Therapeutic Pipeline like by Drug, Company and Stage of Development?
What Microbiome Therapeutics are in the Clostridium Difficile Infection Pipeline?
Who are the Major Players in the Therapeutic and Diagnostic Spaces?
What will the Microbiome Therapeutic Market be Worth in 2023?
What will the Microbiome Therapeutic Sub-Markets (Gastrointestinal, Metabolic, Cancer, Neurological, Autoimmune, Skin) be Worth in 2023?
What will the Microbiome Diagnostic Market be Worth in 2023?
What will the Microbiome Diagnostic Sub-Markets (Gastrointestinal, Metabolic, Cancer, Neurological, Autoimmune, Skin) be Worth in 2023?
What are the Main Drivers, Threats and Opportunities of these Markets?
What were the Most Influential Market Deals to Date?
How Much Venture Capital has Been Invested in the Microbiome Industry?
What Major Microbiome Companies have Received Investment?
What Microbiota are Associated with Cancer Development?
How does Gut Dysbiosis influence the Host Inflammatory Response?
Is there an Association Between the Development of Diabetes and Our Microbiota?
How does Clostridium difficile Infection Impact the Microbiome?
What Host-Microbe Interactions Occur During the Pathogenesis of Dental Caries?
During Cirrhosis of the Liver, What Brain Dysfunction Occurs Due to Gut Dysbiosis?
What are the Main Therapeutic Intervention Strategies for Microbiome Dysbiosis
What Safety Requirements are Needed for Microbiome Therapeutics?
What Clinical Trials are Investigating Probiotics and Obesity?
What Clinical Trials are Investigating Probiotics and Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease?
What Clinical Trials are Investigating Probiotics and Irritable Bowel Syndrome?
What Clinical Trials are Investigating Probiotics and Obesity?
How Has the Human Microbiome Project Investigated IBD, Prediabetes and Pregnancy?
How does the Human Microbiome Differ Between Geographical Areas and Bodily Locations?
Countries Covered
Global,North America, Europe, Asia/Pacific, Middle East/Africa, ROC
Contact Info:
Name: Vishal Kalra
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1653034-global-microbiome-therapeutics-diagnostics-market-analysis-forecast-to-2023.html
Source: MarketersMedia
Release ID: 490116
That checked bag? Turns out you won't need it after all. View Entire Post ›
While Europe’s biggest Christmas markets attract millions of visitors every year, many travellers are seeking lesser-known festive destinations. Travel experts at eShores have revealed five underrated Christmas markets worth adding to this year’s winter travel plans based on their festive charm and growing search interest.
For JETOUR, travel means more than discovering new places, it also means respecting and protecting the natural world. As its “Travel+” ecosystem continues to grow, JETOUR is bringing travel, off-road exploration and nature conservation together, encouraging travelers to explore responsibly and help protect the places they visit.
La Dolce Vita Orient Express has embarked on its first international journey, departing from Rome Ostiense on 22 October for Istanbul. The five-day, four-night itinerary marks a significant milestone for the train, extending its journeys beyond Italy and bringing together two of Europe’s emblematic destinations through an exceptional travel experience.
From a music festival in the desert to looking for turtles in the ocean – this could be you this winter. View Entire Post ›
The GR20, a 112-mile hiking trail that bisects the craggy Mediterranean island, is often billed as the continent’s most demanding trek. Here’s an insider’s look.
My fellow Americans, do you know what the capital of Australia is? View Entire Post ›
“Nowadays, we have people listening to AI pop singers,” Chinese-American composer Huang Ruo says during a talk on music and culture in Hong Kong. “They sing so beautifully, but it’s not real. So I do believe theatre and opera are the last dance of humanity.” The 50-year-old New York-based conductor and pianist behind acclaimed cross-cultural operatic projects M. Butterfly (2022) and The Monkey King (2025) made further impassioned statements about performing arts in the modern world. “Seriously,...
From life-altering tragedies to everyday health risks, P.E.I. is taking direct aim at mitigating the toll of drinking. Advocates, are hoping a new provincial alcohol strategy will push Islanders to re-evaluate their relationship with alcohol, while reducing costs that far outweigh the revenue alcohol brings in.
The Registered Disability Savings Plan was intended to be a financial safety net for people with disabilities and the families who care for them. But it's only reaching about a third of those it was designed to help.
The Palm Beaches continue to build on their momentum, giving visitors fresh reasons to return and new experiences to discover with every visit. After welcoming 6.09 million visitors in the first half of 2026, up 6.4% from 2025, The Palm Beaches are building on this success with a pipeline of approximately $500 million in developments set to further strengthen the tourism economy. Across 39 cities and towns, the next wave of openings and experiences is taking shape, making the destination an even more compelling place to visit in the year ahead.
Visitors to Florida’s Kennedy Space Center Visitor Complex can celebrate the innovation, people and legacy behind NASA’s greatest achievements during MAX POWER, an extra-special event taking place 6 – 8 November 2026. The exhibits and experiences at Kennedy Space Center Visitor Complex celebrate NASA’s great achievements: past, present, and future. During MAX POWER, guests will go on an extraordinary journey as the visitor complex further transforms into a showcase of human ingenuity.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.